Anavo Therapeutics BV, a new venture capital-backed company, has been launched in the Netherlands with seed capital of €20 million to investigate the development of drugs targeting phosphatases. Phosphatases are enzymes which, together with kinases, regulate the activity of signalling pathways in the body. But until recently, they have been largely unexplored as a target for therapeutics.
